The evolving therapeutic landscape of diabetic retinopathy

References

• International Diabetes Federation. IDF Diabetes Atlas, 10th ed [Internet]. Brussels, Belgium; 2021 [cited 2022 Oct 19]. Available from: https://diabetesatlas.org.
   Google Scholar
• Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi: 10.2337/dc11-1909
   PubMed Web of Science ®Google Scholar
• Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care. 2004;27(Suppl 1):S84–87. doi: 10.2337/diacare.27.2007.S84
   PubMed Web of Science ®Google Scholar
• Köberlein J, Beifus K, Schaffert C, et al. The economic burden of visual impairment and blindness: a systematic review. BMJ Open. 2013;3(11):e003471. doi: 10.1136/bmjopen-2013-003471
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Lanitis T, Kropat G, et al. Social cost of blindness due to AMD and diabetic retinopathy in the United States in 2020. Ophthalmic Surg Lasers Imaging Retina. 2020;51(S1):S6–S14. doi: 10.3928/23258160-20200401-01
   PubMedGoogle Scholar
• Khoo K, Man REK, Rees G, et al. The relationship between diabetic retinopathy and psychosocial functioning: a systematic review. Qual Life Res. 2019;28(8):2017–2039. doi: 10.1007/s11136-019-02165-1
   PubMed Web of Science ®Google Scholar
• Sharma S, Oliver-Fernandez A, Liu W, et al. The impact of diabetic retinopathy on health-related quality of life. Curr Opin Ophthalmol. 2005;16(3):155. doi: 10.1097/01.icu.0000161227.21797.3d
   PubMedGoogle Scholar
• Kur J, Newman EA, Chan-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog Retin Eye Res. 2012;31(5):377–406. doi: 10.1016/j.preteyeres.2012.04.004
   PubMed Web of Science ®Google Scholar
• Hammes H-P, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes. 2002;51(10):3107–3112. doi: 10.2337/diabetes.51.10.3107
   PubMed Web of Science ®Google Scholar
• Shoshani Y, Harris A, Shoja MM, et al. Impaired ocular blood flow regulation in patients with open-angle glaucoma and diabetes. Clini& Experi Ophthalm. 2012;40(7):697–705. doi:10.1111/j.1442-9071.2012.02778.x
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Harris A, Latkany P, et al. Ocular perfusion abnormalities in diabetes. Acta Ophth Scandi. 2002;80(5):468–477. doi:10.1034/j.1600-0420.2002.800503.x
   PubMedGoogle Scholar
• Roy S, Kim D. Retinal capillary basement membrane thickening: role in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res. 2021;82:100903. doi: 10.1016/j.preteyeres.2020.100903
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Amador AG, Zinman B. Diabetic Retinopathy and Diabetic Macular Edema. Diabetes Care. 2003;26(9):2653–2664. doi:10.2337/diacare.26.9.2653
   PubMed Web of Science ®Google Scholar
• Lim LS, Wong TY. Lipids and diabetic retinopathy. Expert Opin Biol Ther. 2012;12(1):93–105. doi: 10.1517/14712598.2012.641531
   PubMed Web of Science ®Google Scholar
• Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5):343–358. doi: 10.1016/j.preteyeres.2011.05.002
   PubMed Web of Science ®Google Scholar
• Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003;19:442–455. doi: 10.1002/dmrr.415
   PubMed Web of Science ®Google Scholar
• Whitehead M, Osborne A, Widdowson PS, et al. Angiopoietins in diabetic retinopathy: current understanding and therapeutic potential. J Diabetes Res. 2019;2019:e5140521. doi: 10.1155/2019/5140521
   PubMed Web of Science ®Google Scholar
• Michael J. Schematic depiction of the major interactions between endothelial-specific growth factors and their receptors. 2017 [cited 2023 Mar 23]; Available from: https://commons.wikimedia.org/wiki/File:Endothelial_receptors_and_growth_factors_02.svg.
   Google Scholar
• Besenczi R, Tóth J, Hajdu A. A review on automatic analysis techniques for color fundus photographs. Computat Struct Biotechnol J. 2016;14:371–384. doi: 10.1016/j.csbj.2016.10.001
   PubMed Web of Science ®Google Scholar
• Girach A, Lund-Andersen H. Diabetic macular oedema: a clinical overview. Int J Clin Pract. 2007;61(1):88–97. doi: 10.1111/j.1742-1241.2006.01211.x
   PubMed Web of Science ®Google Scholar
• Bhatwadekar AD, Shughoury A, Belamkar A, et al. Genetics of Diabetic Retinopathy, a Leading Cause of Irreversible Blindness in the Industrialized World. Genes. 2021;12(8):1200. doi:10.3390/genes12081200
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from Stereoscopic color fundus photographs—an extension of the modified Airlie house classification: ETDRS report number 10. Ophthalmol. 1991;98(5):786–806. doi: 10.1016/S0161-6420(13)38012-9
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol. 1985;103(12):1796–1806. doi: 10.1001/archopht.1985.01050120030015
   PubMedGoogle Scholar
• Silva PS, Cavallerano JD, Haddad NMN, et al. Peripheral lesions identified on ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4 years. Ophthalmol. 2015;122(5):949–956. doi: 10.1016/j.ophtha.2015.01.008
   PubMed Web of Science ®Google Scholar
• Zhang J, Strauss EC. Sensitive detection of therapeutic efficacy with the ETDRS diabetic retinopathy severity Scale. Clin Ophthalmol. 2020;14:4385–4393.
   PubMed Web of Science ®Google Scholar
• Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmol. 2003;110(9):1677–1682. doi: 10.1016/S0161-6420(03)00475-5
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837–853. doi: 10.1016/S0140-6736(98)07019-6
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The Effect of intensive treatment of Diabetes on the development and progression of long-term complications in insulin-dependent Diabetes mellitus. N Engl J Med. 1993;329(14):977–986. doi: 10.1056/NEJM199309303291401
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 Diabetes. N Engl J Med. 2008;358(24):2545–2559. doi: 10.1056/NEJMoa0802743
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430. doi: 10.1016/S0140-6736(10)60576-4
   PubMed Web of Science ®Google Scholar
• Martin CL, Trapani VR, Backlund J-Y, et al. Physical function in middle-aged and older adults with type 1 diabetes: long-term follow-up of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2022;45:2037–2045. doi: 10.2337/dc21-2119
   PubMed Web of Science ®Google Scholar
• Nathan DM. The Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9–16. doi: 10.2337/dc13-2112
   PubMed Web of Science ®Google Scholar
• Ipp E, Kumar M. A clinical conundrum: intensifying glycemic control in the presence of advanced diabetic retinopathy. Diabetes Care. 2021;44(10):2192–2193. doi: 10.2337/dci21-0029
   PubMed Web of Science ®Google Scholar
• Azad N, Agrawal L, Bahn G, et al. Eye outcomes in Veteran Affairs Diabetes trial (VADT) after 17 Years. Diabetes Care. 2021;44(10):2397–2402. doi: 10.2337/dc20-2882
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 Diabetes. N Engl J Med. 2008;358(24):2560–2572. doi: 10.1056/NEJMoa0802987
   PubMed Web of Science ®Google Scholar
• Wong T, Mitchell P. The eye in hypertension. Lancet. 2007;369(9559):425–435. doi: 10.1016/S0140-6736(07)60198-6
   PubMed Web of Science ®Google Scholar
• Aroca PR, Salvat M, Fernández J, et al. Risk factors for diffuse and focal macular edema. J Diabetes Complications. 2004;18(4):211–215. doi: 10.1016/S1056-8727(03)00038-2
   PubMed Web of Science ®Google Scholar
• Vitale S, Maguire MG, Murphy RP, et al. Clinically significant macular edema in type I diabetes. Incidence and risk factors. Ophthalmol. 1995;102(8):1170–1176. doi: 10.1016/S0161-6420(95)30894-9
   PubMed Web of Science ®Google Scholar
• Do DV, Wang X, Vedula SS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Of Systematic Reviews. 2015 [cited 2022 Dec 24]; Available from: https://www-cochranelibrary-com.proxy.ulib.uits.iu.edu/cdsr/doi/10.1002/14651858.CD006127.pub2/full.
   Google Scholar
• Assmann G, Schulte H. The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988;116(6):1713–1724. doi: 10.1016/0002-8703(88)90220-7
   PubMed Web of Science ®Google Scholar
• Chou Y, Ma J, Su X, et al. Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy. Lipids Health Dis. 2020;19(1):1–12. doi: 10.1186/s12944-020-01415-3
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 Diabetes. N Engl J Med. 2010;363(3):233–244. doi: 10.1056/NEJMoa1001288
   PubMed Web of Science ®Google Scholar
• Shi R, Zhao L, Wang F, et al. Effects of lipid-lowering agents on diabetic retinopathy: a meta-analysis and systematic review. Int J Ophthalmol. 2018;11(2):287–295. doi: 10.18240/ijo.2018.02.18
   PubMed Web of Science ®Google Scholar
• Keech A, Mitchell P, Summanen P, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687–1697. doi: 10.1016/S0140-6736(07)61607-9
   PubMed Web of Science ®Google Scholar
• Meer E, Bavinger JC, Yu Y, et al. Association of fenofibrate use and the risk of progression to vision-threatening diabetic retinopathy. JAMA Ophthalmol. 2022;140(5):529–532. doi: 10.1001/jamaophthalmol.2022.0633
   PubMed Web of Science ®Google Scholar
• Frank RN. Use of fenofibrate in the management of diabetic retinopathy—large population analyses. JAMA Ophthalmol. 2022;140(5):533. doi: 10.1001/jamaophthalmol.2022.0634
   PubMed Web of Science ®Google Scholar
• Sramek C, Paulus Y, Nomoto H, et al. Dynamics of retinal photocoagulation and rupture. J Biomed Opt. 2009;14(3):034007. doi: 10.1117/1.3130282
   PubMed Web of Science ®Google Scholar
• Stefánsson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmologica Scandinavica. 2001;79(5):435–440. doi: 10.1034/j.1600-0420.2001.790502.x
   PubMedGoogle Scholar
• Everett LA, Paulus YM. Laser therapy in the treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2021;21(9):35. doi: 10.1007/s11892-021-01403-6
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmol. 1981;88(7):583–600. doi: 10.1016/S0161-6420(81)34978-1
   PubMed Web of Science ®Google Scholar
• The Early Treatment Diabetic Retinopathy Study Research Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: early treatment diabetic retinopathy study report no. 3. Int Ophthalmol Clin. 1987;27(4):254. doi: 10.1097/00004397-198702740-00005
   PubMedGoogle Scholar
• Chew EY, Ferris FL, Csaky KG, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmol. 2003;110(9):1683–1689. doi: 10.1016/S0161-6420(03)00579-7
   PubMed Web of Science ®Google Scholar
• Reddy SV, Husain D. Panretinal photocoagulation: a review of complications. Semin Ophthalmol. 2018;33:83–88. doi: 10.1080/08820538.2017.1353820
   PubMed Web of Science ®Google Scholar
• The Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Ophthalmol. 1987;94(7):761–774. doi: 10.1016/S0161-6420(87)33527-4
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report no. 4. Int Ophthalmol Clin. 1987;27(4):265–272. doi: 10.1097/00004397-198702740-00006
   PubMedGoogle Scholar
• Herold TR, Langer J, Vounotrypidis E, et al. 3-year-data of combined navigated laser photocoagulation (Navilas) and intravitreal ranibizumab compared to ranibizumab monotherapy in DME patients. PLoS One. 2018;13(8):e0202483. doi: 10.1371/journal.pone.0202483
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmol. 2011;118(4):615–625. doi: 10.1016/j.ophtha.2011.01.031
   PubMed Web of Science ®Google Scholar
• Payne JF, Wykoff CC, Clark WL, et al. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. Br J Ophthalmol. 2021;105(2):253–257. doi: 10.1136/bjophthalmol-2020-316176
   PubMed Web of Science ®Google Scholar
• Prünte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100(6):787–795. doi: 10.1136/bjophthalmol-2015-307249
   PubMed Web of Science ®Google Scholar
• Zur D, Loewenstein A. Should we still be performing macular laser for non-centre involving diabetic macular oedema? yes. Eye. 2022;36(3):483–484. doi: 10.1038/s41433-021-01793-7
   PubMed Web of Science ®Google Scholar
• Mueller I, Talks JS. Should we still be performing macular laser for non-centre involving diabetic macular oedema? no. Eye. 2022;36(3):485–486. doi: 10.1038/s41433-021-01787-5
   PubMed Web of Science ®Google Scholar
• Scholz P, Altay L, Fauser S. A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther. 2017;34(7):1528–1555. doi: 10.1007/s12325-017-0559-y
   PubMed Web of Science ®Google Scholar
• Silva PS, Sun JK, Aiello LP. Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. Semin Ophthalmol. 2009;24(2):93–99. doi: 10.1080/08820530902800355
   PubMed Web of Science ®Google Scholar
• Lattanzio R, Cicinelli MV, Bandello F. Intravitreal Steroids in Diabetic Macular Edema. In: Bandello F, Zarbin M Lattanzio R, et al.,editors Developments in ophthalmology [Internet]. S. Karger AG. 2017; p. 78–90. cited 2023 Jan 7. doi: 10.1159/000459691
   Google Scholar
• Gillies MC, McAllister IL, Zhu M, et al. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmol. 2011;118(5):866–872. doi: 10.1016/j.ophtha.2010.09.029
   PubMed Web of Science ®Google Scholar
• Gillies MC, Sutter FKP, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema - two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmol. 2006;113:1533–1538. doi: 10.1016/j.ophtha.2006.02.065
   PubMed Web of Science ®Google Scholar
• Grover DA, Li T, Chong CC Intravitreal steroids for macular edema in diabetes. Cochrane Database Of Systematic Reviews. 2008 [cited 2023 Jan 7]; Available from: https://www-cochranelibrary-com.proxy.ulib.uits.iu.edu/cdsr/doi/10.1002/14651858.CD005656.pub2/full.
   Google Scholar
• Jeon S, Lee WK. Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab. Retina. 2014;34(8):1606. doi: 10.1097/IAE.0000000000000109
   PubMed Web of Science ®Google Scholar
• Larsson J, Kifley A, Zhu M, et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmol. 2009;87(3):275–280. doi: 10.1111/j.1755-3768.2008.01245.x
   PubMed Web of Science ®Google Scholar
• Maia OO, Takahashi BS, Costa RA, et al. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am J Ophthalmol. 2009;147(2):291–297.e2. doi: 10.1016/j.ajo.2008.08.024
   PubMed Web of Science ®Google Scholar
• Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmol. 2009;116(5):902–913. doi: 10.1016/j.ophtha.2009.02.002
   PubMed Web of Science ®Google Scholar
• Lam DSC, Chan CKM, Mohamed S, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmol. 2007;114(12):2162–2167.e1. doi: 10.1016/j.ophtha.2007.02.006
   PubMed Web of Science ®Google Scholar
• Kang SW, Sa H-S, Cho HY, et al. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophtalmol. 2006;124:653–658. doi: 10.1001/archopht.124.5.653
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmol. 2010;117(6):1064–1077.e35. doi: 10.1016/j.ophtha.2010.02.031
   PubMed Web of Science ®Google Scholar
• Zein WM, Noureddin BN, Jurdi FA, et al. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. Retina. 2006;26(2):137–142. doi: 10.1097/00006982-200602000-00002
   PubMed Web of Science ®Google Scholar
• Liu L, Wu X, Geng J, et al. IVTA as adjunctive treatment to PRP and MPC for PDR and macular edema: a meta-analysis. PLoS One. 2012;7(9):e44683. doi: 10.1371/journal.pone.0044683
   PubMed Web of Science ®Google Scholar
• Avci R, Kaderli B. Intravitreal triamcinolone injection for chronic diabetic macular oedema with severe hard exudates. Graefes Arch Clin Exp Ophthalmol. 2006;244(1):28–35. doi: 10.1007/s00417-005-0069-5
   PubMed Web of Science ®Google Scholar
• Choi KS, Chung J, Lim SH. Laser photocoagulation combined with intravitreal triamcinolone acetonide injection in proliferative diabetic retinopathy with macular edema. Korean J Ophthalmol. 2007;21(1):11–17. doi: 10.3341/kjo.2007.21.1.11
   PubMedGoogle Scholar
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmol. 2008;115(9):1447–1459.e10. doi: 10.1016/j.ophtha.2008.06.015
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Beck RW, Edwards AR. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245–251.
   PubMed Web of Science ®Google Scholar
• Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmol. 2005;112(4):593–598. doi: 10.1016/j.ophtha.2004.10.042
   PubMed Web of Science ®Google Scholar
• Mishra C, Lalitha P, Rameshkumar G, et al. Incidence of endophthalmitis after intravitreal injections: risk factors, microbiology profile, and clinical outcomes. Ocul Immunol Inflamm. 2018;26:559–568. doi: 10.1080/09273948.2018.1430238
   PubMed Web of Science ®Google Scholar
• VanderBeek BL, Bonaffini SG, Ma L. The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmol. 2015;122(11):2311–2315.e1. doi: 10.1016/j.ophtha.2015.07.005
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmol. 2014;121(10):1904–1914. doi: 10.1016/j.ophtha.2014.04.024
   PubMed Web of Science ®Google Scholar
• Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophtalmol. 2010;128:289–296. doi: 10.1001/archophthalmol.2010.21
   PubMed Web of Science ®Google Scholar
• Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmol. 2013;120(9):1843–1851. doi: 10.1016/j.ophtha.2013.02.018
   PubMed Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915. doi: 10.1097/IAE.0b013e318206d18c
   PubMed Web of Science ®Google Scholar
• Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmol. 2014;121(12):2473–2481. doi: 10.1016/j.ophtha.2014.07.002
   PubMed Web of Science ®Google Scholar
• Iglicki M, Zur D, Busch C, et al. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-Pro-DEX study. Acta Diabetol. 2018;55:541–547. doi: 10.1007/s00592-018-1117-z
   PubMed Web of Science ®Google Scholar
• Chang-Lin J-E, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80–86. doi: 10.1167/iovs.10-5285
   PubMed Web of Science ®Google Scholar
• Montes Rodríguez P, Mateo Gabás J, Esteban Floría O, et al. Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema. Cost Eff Resour Allocation. 2022;20(1):61. doi: 10.1186/s12962-022-00401-z
   PubMed Web of Science ®Google Scholar
• Campochiaro P A et al . (2010). Sustained Ocular Delivery of Fluocinolone Acetonide by an Intravitreal Insert. Ophthalmology, 117(7), 1393–1399.e3. 10.1016/j.ophtha.2009.11.024
   PubMed Web of Science ®Google Scholar
• Campochiaro PA. Long-term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema. Ophthalmology. 2011;118(4):626–635.e2. doi: 10.1016/j.ophtha.2010.12.028
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous Inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmol. 2012;119(10):2125–2132. doi: 10.1016/j.ophtha.2012.04.030
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmol. 2014;121(10):1892–1903.e3. doi: 10.1016/j.ophtha.2014.04.019
   PubMed Web of Science ®Google Scholar
• Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–1264. doi: 10.1016/j.cell.2019.01.021
   PubMed Web of Science ®Google Scholar
• Witmer AN, Vrensen GFJM, Van Noorden CJF, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29.
   PubMed Web of Science ®Google Scholar
• Stitt AW, Curtis TM, Chen M, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156–186. doi: 10.1016/j.preteyeres.2015.08.001
   PubMed Web of Science ®Google Scholar
• Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmol. 2015;122(7):1375–1394. doi: 10.1016/j.ophtha.2015.03.024
   PubMed Web of Science ®Google Scholar
• Li AS, Veerappan M, Mittal V, et al. Anti-VEGF agents in the management of diabetic macular edema. Expert Rev Ophthalmol. 2020;15(5):285–296. doi: 10.1080/17469899.2020.1806713
   Web of Science ®Google Scholar
• Ehlers JP, Yeh S, Maguire MG, et al. Intravitreal pharmacotherapies for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmol. 2022;129(1):88–99. doi: 10.1016/j.ophtha.2021.07.009
   PubMed Web of Science ®Google Scholar
• Chatziralli I, Loewenstein A. Intravitreal anti-vascular endothelial growth factor agents for the treatment of diabetic retinopathy: a review of the literature. Pharmaceutics. 2021;13(8):1137. doi: 10.3390/pharmaceutics13081137
   PubMed Web of Science ®Google Scholar
• EWM N, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5:123–132. doi: 10.1038/nrd1955
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–870. doi: 10.1097/01.iae.0000242842.14624.e7
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmol. 2009;116(11):2175–2181.e1. doi: 10.1016/j.ophtha.2009.04.023
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Boyer D, et al. Twenty-four-month outcomes of the ranibizumab for edema of the macula in Diabetes - Protocol 3 with high dose (READ-3) study. Ophthalmol. 2016;123:2581–2587. doi: 10.1016/j.ophtha.2016.08.040
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study). Diabetes Care. 2010;33(11):2399–2405. doi: 10.2337/dc10-0493
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW, et al.; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077.e35.
   PubMed Web of Science ®Google Scholar
• Bressler SB, Glassman AR, Almukhtar T, et al. Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. Am J Ophthalmol. 2016;164:57–68. doi: 10.1016/j.ajo.2015.12.025
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmol. 2016;123:1351–1359.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of Individualized ranibizumab treatment in patients with diabetic macular edema: the restore extension study. Ophthalmol. 2014;121(5):1045–1053. doi: 10.1016/j.ophtha.2013.11.041
   PubMed Web of Science ®Google Scholar
• Mitchell P, Massin P, Bressler S, et al. Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE extension study. Curr Med Res Opin. 2015;31(11):1967–1975. doi: 10.1185/03007995.2015.1081880
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Li X, Koh A, et al. The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmol. 2015;122(7):1402–1415. doi: 10.1016/j.ophtha.2015.02.006
   PubMed Web of Science ®Google Scholar
• Bressler NM, Varma R, Suñer IJ, et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmol. 2014;121:2461–2472.
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmol. 2013;120(10):2013–2022. doi: 10.1016/j.ophtha.2013.02.034
   PubMed Web of Science ®Google Scholar
• Maturi RK, Glassman AR, Liu D, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR Network Phase 2 randomized clinical trial. JAMA Ophthalmol. 2018;136(1):29–38. doi: 10.1001/jamaophthalmol.2017.4914
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Eichenbaum DA, Roth DB, et al. Ranibizumab induces regression of diabetic retinopathy in most patients at high risk of progression to proliferative diabetic retinopathy. Ophthalmol Retina. 2018;2(10):997–1009. doi: 10.1016/j.oret.2018.06.005
   PubMedGoogle Scholar
• Bressler SB, Odia I, Glassman AR, et al. Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR.Net Protocol I 5-year report. Retina. 2018;38(10):1896–1904. doi: 10.1097/IAE.0000000000002302
   PubMed Web of Science ®Google Scholar
• Lang GE, Stahl A, Voegeler J, et al. Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy – the PRIDE study. Acta Ophthalmol. 2020;98(5):e530–e539. doi: 10.1111/aos.14312
   PubMed Web of Science ®Google Scholar
• Figueira J, Fletcher E, Massin P, et al. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk Proliferative Diabetic Retinopathy (PROTEUS study). Ophthalmol. 2018;125(5):691–700. doi: 10.1016/j.ophtha.2017.12.008
   PubMed Web of Science ®Google Scholar
• Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018;136(10):1138–1148. doi: 10.1001/jamaophthalmol.2018.3255
   PubMed Web of Science ®Google Scholar
• Ip MS, Domalpally A, Sun JK, et al. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmol. 2015;122(2):367–374. doi: 10.1016/j.ophtha.2014.08.048
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013;131(3):283–293. doi: 10.1001/jamaophthalmol.2013.2015
   PubMed Web of Science ®Google Scholar
• Chelala E, Nehme J, El Rami H, et al. Efficacy of intravitreal ranibizumab injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy. Retina. 2018;38(6):1127–1133. doi: 10.1097/IAE.0000000000001673
   PubMed Web of Science ®Google Scholar
• Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized Phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmol. 2022;129(3):295–307. doi: 10.1016/j.ophtha.2021.09.016
   PubMed Web of Science ®Google Scholar
• Susvimo Prescribing Information. Package insert. [Internet]. Genentech, Inc. 2022 [cited 2023 Mar 15]; Available from: https://www.gene.com/download/pdf/susvimo_prescribing.pdf.
   Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):331–335. doi: 10.3928/1542-8877-20050701-14
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A Phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmol. 2007;114(10):1860–1867.e7. doi: 10.1016/j.ophtha.2007.05.062
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203. doi: 10.1056/NEJMoa1414264
   PubMed Web of Science ®Google Scholar
• Heier JS, Bressler NM, Avery RL, et al. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol. 2016;134(1):95–99. doi: 10.1001/jamaophthalmol.2015.4110
   PubMed Web of Science ®Google Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal Bevacizumab Or Laser Therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophtalmol. 2012;130(8):972–979. doi: 10.1001/archophthalmol.2012.393
   PubMed Web of Science ®Google Scholar
• Schmidinger G, Maar N, Bolz M, et al. Repeated intravitreal bevacizumab (Avastin®) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol. 2011;89(1):76–81. doi: 10.1111/j.1755-3768.2009.01622.x
   PubMed Web of Science ®Google Scholar
• Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized Double-masked clinical trial. Eur J Ophthalmol. 2008;18(2):263–269. doi: 10.1177/112067210801800215
   PubMed Web of Science ®Google Scholar
• Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study): 12-month data: report 2. Ophthalmol. 2010;117(6):1078–1086.e2. doi: 10.1016/j.ophtha.2010.03.045
   PubMed Web of Science ®Google Scholar
• Ford JA, Elders A, Shyangdan D, et al. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ. 2012;345(aug13 1):e5182. doi: 10.1136/bmj.e5182
   PubMedGoogle Scholar
• Bressler SB, Liu D, Glassman AR, et al. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab. JAMA Ophthalmol. 2017;135(6):558–568. doi: 10.1001/jamaophthalmol.2017.0821
   PubMed Web of Science ®Google Scholar
• Holekamp N, Duff SB, Rajput Y, et al. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data. J Med Econ. 2020;23(3):287–296. doi: 10.1080/13696998.2019.1666855
   PubMed Web of Science ®Google Scholar
• Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol. 2009;54(3):372–400. doi: 10.1016/j.survophthal.2009.02.004
   PubMed Web of Science ®Google Scholar
• Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012;11(4):269–270. doi: 10.1038/nrd3700
   PubMed Web of Science ®Google Scholar
• Korobelnik J-F, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmol. 2014;121(11):2247–2254. doi: 10.1016/j.ophtha.2014.05.006
   PubMed Web of Science ®Google Scholar
• Heier JS, Korobelnik J-F, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmol. 2016;123(11):2376–2385. doi: 10.1016/j.ophtha.2016.07.032
   PubMed Web of Science ®Google Scholar
• Brown DM, Wykoff CC, Boyer D, et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the panorama randomized clinical trial. JAMA Ophthalmol. 2021;139(9):946–955. doi: 10.1001/jamaophthalmol.2021.2809
   PubMed Web of Science ®Google Scholar
• Maturi RK, Glassman AR, Josic K, et al. Effect of Intravitreous anti–vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol W randomized clinical trial. JAMA Ophthalmol. 2021;139(7):701–712. doi: 10.1001/jamaophthalmol.2021.0606
   PubMed Web of Science ®Google Scholar
• Antoszyk AN, Glassman AR, Beaulieu WT, et al. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2020;324(23):2383–2395. doi: 10.1001/jama.2020.23027
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals, Inc. EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) [Internet]. Regeneron Pharmaceuticals. 2023 [cited 2023 Aug 19]. Available from: https://investor.regeneron.com/news-releases/news-release-details/eylea-hd-aflibercept-injection-8-mg-approved-fda-treatment-wet/.
   Google Scholar
• Ross EL, Hutton DW, Stein JD, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016;134(8):888–896. doi: 10.1001/jamaophthalmol.2016.1669
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol. 2021;105(2):216–221. doi: 10.1136/bjophthalmol-2020-315933
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Bracha P, Pollack J, et al. Real-world outcomes of anti–vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2018;2(12):1179–1187. doi: 10.1016/j.oret.2018.06.004
   PubMedGoogle Scholar
• Ciulla TA, Hussain RM, Taraborelli D, et al. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema. Ophthalmology Retina. 2022;6(9):796–806. doi:10.1016/j.oret.2022.03.021
   PubMedGoogle Scholar
• Ghasemi Falavarjani K, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27(7):787–794. doi: 10.1038/eye.2013.107
   PubMed Web of Science ®Google Scholar
• Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the Phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmol. 2021;128(1):89–99. doi: 10.1016/j.ophtha.2020.06.028
   PubMed Web of Science ®Google Scholar
• Kuo BL, Singh RP. Brolucizumab for the treatment of diabetic macular edema. Curr Opin Ophthalmol. 2022;33(3):167. doi: 10.1097/ICU.0000000000000849
   PubMed Web of Science ®Google Scholar
• Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-week results from two phase III Pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157–172. doi: 10.1016/j.ajo.2022.01.004
   PubMed Web of Science ®Google Scholar
• Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmol. 2020;127(10):1345–1359. doi: 10.1016/j.ophtha.2020.04.017
   PubMed Web of Science ®Google Scholar
• Baumal CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021;5(6):519–527. doi: 10.1016/j.oret.2020.09.020
   PubMedGoogle Scholar
• Cai S, Yang Q, Li X, et al. The efficacy and safety of aflibercept and conbercept in diabetic macular edema. Drug Des Devel Ther. 2018;12:3471–3483. doi: 10.2147/DDDT.S177192
   PubMed Web of Science ®Google Scholar
• Liu K, Wang H, He W, et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol. 2022;106(10):1436–1443. doi: 10.1136/bjophthalmol-2020-318690
   PubMed Web of Science ®Google Scholar
• Liang H, Huang X, Ngo W, et al. KSI-301: an anti-VEGF antibody biopolymer conjugate with extended half-life for treatment of neovascular retinal diseases. Invest Ophthalmol Visual Sci. 2018;59:211.
   Web of Science ®Google Scholar
• Kodiak sciences announces top-line results from its initial Phase 2b/3 study of KSI-301 in patients with neovascular (Wet) age-related macular degeneration | kodiak sciences Inc. [cited 2023 Jan 10]; Available from: https://ir.kodiak.com/news-releases/news-release-details/kodiak-sciences-announces-top-line-results-its-initial-phase-2b3/.
   Google Scholar
• Kodiak Sciences, Inc. Kodiak sciences reports Positive topline results from BEACON Phase 3 study of tarcocimab tedromer (KSI-301) in patients with retinal vein occlusion. [cited 2023 Jan 15]; Available from: https://www.prnewswire.com/news-releases/kodiak-sciences-reports-positive-topline-results-from-beacon-phase-3-study-of-tarcocimab-tedromer-ksi-301-in-patients-with-retinal-vein-occlusion-301601194.html.
   Google Scholar
• Ophthea Limited. Opthea reports Positive Phase 2a trial results of OPT-302 in diabetic macular edema [Internet]. GlobeNewswire News Room. 2020 [cited 2023 Jul 25]; Available from: https://www.globenewswire.com/en/news-release/2020/06/09/2045972/0/en/Opthea-Reports-Positive-Phase-2a-Trial-Results-of-OPT-302-in-Diabetic-Macular-Edema.html.
   Google Scholar
• Cébe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci. 2006;63(5):601. doi: 10.1007/s00018-005-5426-3
   PubMed Web of Science ®Google Scholar
• Gupta N, Mansoor S, Sharma A, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7:4–10. doi: 10.2174/1874364101307010004
   PubMedGoogle Scholar
• Cabral T, Lima LH, Mello LGM, et al. Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers. Ophthalmol Retina. 2018;2(1):31–37. doi: 10.1016/j.oret.2017.04.004
   PubMedGoogle Scholar
• Bendell JC, Patel MR, Moore KN, et al. Phase I, first‐in‐human, dose‐escalation study to evaluate the safety, tolerability, and pharmacokinetics of vorolanib in patients with advanced solid tumors. Oncology. 2019;24:455–e121. doi: 10.1634/theoncologist.2018-0740
   Google Scholar
• Kaiser PK, Ciulla T, Kansara V. Suprachoroidal CLS-AX (axitinib injectable suspension), as a potential long-acting therapy for neovascular age-related macular degeneration (nAMD). Invest Ophthalmol Vis Sci. 2020;61:3977.
   Google Scholar
• Clearside Biomedical, Inc. Clearside Biomedical announces Positive results in safety, durability and Biologic Effect in OASIS Phase 1/2a clinical trial of suprachoroidal CLS-AX (axitinib injectable suspension) in wet AMD patients [Internet]. GlobeNewswire News Room. 2022 [cited 2023 Jan 15]; Available from: https://www.globenewswire.com/en/news-release/2022/11/09/2551845/0/en/Clearside-Biomedical-Announces-Positive-Results-in-Safety-Durability-and-Biologic-Effect-in-OASIS-Phase-1-2a-Clinical-Trial-of-Suprachoroidal-CLS-AX-axitinib-injectable-suspension-.html.
   Google Scholar
• Wong JG, Chang A, Guymer RH, et al. Phase 1 study of an intravitreal axitinib hydrogel-based implant for the treatment of Neovascular Age-Related Macular Degeneration (nAMD). Invest Ophthalmol Visual Sci. 2021;62:218.
   Google Scholar
• Heier JS, Singh RP, Wykoff CC, et al. The angiopoietin/tie pathway in retinal vascular diseases: a review. Retina. 2021;41(1):1. doi: 10.1097/IAE.0000000000003003
   PubMed Web of Science ®Google Scholar
• Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmol. 2019;126(8):1155–1170. doi: 10.1016/j.ophtha.2019.03.023
   PubMed Web of Science ®Google Scholar
• Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–740. doi: 10.1016/S0140-6736(22)00010-1
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741–755. doi: 10.1016/S0140-6736(22)00018-6
   PubMed Web of Science ®Google Scholar
• Taylor L, {CM~Basel}. FDA approves Roche’s vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss. 2022.
   Google Scholar
• Van Hove I, Hu T-T, Beets K, et al. Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration. Prog Retin Eye Res. 2021;85:100966. doi: 10.1016/j.preteyeres.2021.100966
   PubMed Web of Science ®Google Scholar
• Bhatwadekar AD, Kansara V, Luo Q, et al. Anti-integrin therapy for retinovascular diseases. Expert Opin Investig Drugs. 2020;29(9):935–945. doi: 10.1080/13543784.2020.1795639
   PubMed Web of Science ®Google Scholar
• Shaw LT, Mackin A, Shah R, et al. Risuteganib—a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema. Expert Opin Investig Drugs. 2020;29(6):547–554. doi: 10.1080/13543784.2020.1763953
   PubMed Web of Science ®Google Scholar
• Quiroz-Mercado H, Boyer DS, Campochiaro PA, et al. Randomized, prospective, Double-masked, controlled Phase 2b trial to evaluate the safety & efficacy of ALG-1001 (Luminate®) in diabetic macular edema. Invest Ophthalmol Visual Sci. 2018;59:1960.
   Web of Science ®Google Scholar
• Khanani AM, Patel SS, Gonzalez VH, et al. Phase 1 study of THR-687, a novel, highly potent integrin antagonist for the treatment of diabetic macular edema. Ophthalmol Sci. 2021;1(3):100040. doi: 10.1016/j.xops.2021.100040
   PubMedGoogle Scholar
• Kuppermann BD, Group on behalf of the OS. Inhibition of 5β1 integrin in neovascular AMD - A Phase 1 study. Invest Ophthalmol Visual Sci. 2010; 51:1252.
   Web of Science ®Google Scholar
• Cherukury M, Wu A, Chang B, et al. AG-73305, a novel multi-specific Fc-fusion protein for the treatment of diabetic macular edema. Invest Ophthalmol Visual Sci. 2019;60:3663.
   Web of Science ®Google Scholar
• Askew BC, Furuya T, Edwards DS. Ocular distribution and pharmacodynamics of SF0166, a topically administered αvβ3 integrin antagonist, for the treatment of retinal diseases. J Pharmacol Exp Ther. 2018;366(2):244–250. doi: 10.1124/jpet.118.248427
   PubMed Web of Science ®Google Scholar
• Edwards D, Boyer DS, Kaiser PK, et al. First-in human study of SF0166 topical ophthalmic solution in patients with diabetic macular edema. Invest Ophthalmol Visual Sci. 2018;59:1961.
   Google Scholar
• Boyer DS, Kaiser PK, Magrath GN, et al. The safety and biological activity of OTT166, a novel topical selective integrin inhibitor for the treatment of diabetic eye disease: a phase 1b study. Ophthalmic Surg Lasers Imaging Retina. 2022;53(10):553–560. doi: 10.3928/23258160-20220923-02
   PubMed Web of Science ®Google Scholar
• Ciulla T, Pennesi ME, Kiss S, et al. DNA- and RNA-based gene therapies in Ophthalmology. Int Ophthalmol Clin. 2021;61(3):3–16. doi: 10.1097/IIO.0000000000000359
   Google Scholar
• Shughoury A, Ciulla TA, Bakall B, et al. Genes and gene therapy in inherited retinal disease. Int Ophthalmol Clin. 2021;61(4):3. doi: 10.1097/IIO.0000000000000377
   PubMedGoogle Scholar
• Khanani AM, Thomas MJ, Aziz AA, et al. Review of gene therapies for age-related macular degeneration. Eye. 2022;36(2):303–311. doi: 10.1038/s41433-021-01842-1
   PubMed Web of Science ®Google Scholar
• Buggage RR, Bordet T. Gene therapy for uveitis. Int Ophthalmol Clin. 2021;61(4):249. doi: 10.1097/IIO.0000000000000369
   PubMedGoogle Scholar
• Wang J-H, Roberts GE, Liu G-S. Updates on gene therapy for diabetic retinopathy. Curr Diab Rep. 2020;20(7):22. doi: 10.1007/s11892-020-01308-w
   PubMed Web of Science ®Google Scholar
• Maguire AM, Russell S, Chung DC, et al. Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years. Ophthalmol. 2021 [cited 2021 Jul 17];128(10):1460–1468. doi: 10.1016/j.ophtha.2021.03.031
   PubMed Web of Science ®Google Scholar
• Klufas M. Suprachoroidal delivery of RGX-314 for diabetic retinopathy without CI-DME: results from the Phase II ALTITUDE study. Angiogenesis Exudation Degeneration. 2022.
   Google Scholar
• Maulik N. Redox signaling of angiogenesis. Antioxid Redox Signaling. 2002;4(5):805–815. doi: 10.1089/152308602760598963
   PubMed Web of Science ®Google Scholar
• Hartman GD, Lambert-Cheatham NA, Kelley MR, et al. Inhibition of APE1/Ref-1 for neovascular eye diseases: from biology to therapy. Int J Mol Sci. 2021;22(19):10279. doi: 10.3390/ijms221910279
   PubMed Web of Science ®Google Scholar
• Li Y, Liu X, Zhou T, et al. Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization. Redox Biol. 2014;2:485–494. doi: 10.1016/j.redox.2014.01.023
   PubMed Web of Science ®Google Scholar
• Pasha SPBS, Sishtla K, Sulaiman RS, et al. Ref-1/APE1 inhibition with novel small molecules blocks ocular neovascularization. J Pharmacol Exp Ther. 2018;367(1):108–118. doi: 10.1124/jpet.118.248088
   PubMed Web of Science ®Google Scholar
• Ocuphire announces topline results from ZETA-1 Phase 2 trial of oral APX3330 in diabetic retinopathy and plans for end-of-phase 2 meeting with FDA [Internet]. Ocuphire Pharma, Inc. 2023 [cited 2023 Mar 15]; Available from: https://www.ocuphire.com/news-media/press-releases/detail/395/ocuphire-announces-topline-results-from-zeta-1-phase-2.
   Google Scholar
• Nourinia R, Nakao S, Zandi S, et al. ROCK inhibitors for the treatment of ocular diseases. Br J Ophthalmol. 2018;102(1):1–5. doi: 10.1136/bjophthalmol-2017-310378
   Web of Science ®Google Scholar
• Hahn MG, Lampe T, El Sheikh S, et al. Discovery of the soluble guanylate cyclase activator runcaciguat (BAY 1101042). J Med Chem. 2021;64(9):5323–5344. doi: 10.1021/acs.jmedchem.0c02154
   PubMed Web of Science ®Google Scholar
• Kumawat VS, Kaur G. Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications. Eur J Pharmacol. 2019;862:172628. doi: 10.1016/j.ejphar.2019.172628
   PubMed Web of Science ®Google Scholar
• Mugisho OO, Aryal J, Shorne A, et al. Orally delivered Connexin43 hemichannel blocker, tonabersat, inhibits vascular breakdown and inflammasome activation in a mouse model of diabetic retinopathy. Int J Mol Sci. 2023;24:3876. doi: 10.3390/ijms24043876
   PubMed Web of Science ®Google Scholar
• Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014;2014:CD008721. doi: 10.1002/14651858.CD008721.pub2
   PubMedGoogle Scholar
• Gross JG, Glassman AR, Jampol LM, et al.; Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs Intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–2146.
   PubMed Web of Science ®Google Scholar
• Gao S, Lin Z, Shen X. Anti-vascular endothelial growth factor therapy as an alternative or adjunct to Pan-retinal photocoagulation in treating proliferative diabetic retinopathy: meta-analysis of randomized trials. Front Pharmacol. 2020 [cited 2023 Jan 8];11. doi: 10.3389/fphar.2020.00849
   Web of Science ®Google Scholar
• Obeid A, Gao X, Ali FS, et al. Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections. Ophthalmol. 2018;125:1386–1392.
   PubMed Web of Science ®Google Scholar
• Jhaveri CD, Glassman AR, Ferris FL, et al. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. N Engl J Med. 2022;387(8):692–703. doi: 10.1056/NEJMoa2204225
   PubMed Web of Science ®Google Scholar
• Tomita Y, Lee D, Tsubota K, et al. Updates on the current treatments for diabetic retinopathy and possibility of future oral therapy. J Clin Med. 2021;10:4666. doi: 10.3390/jcm10204666
   PubMed Web of Science ®Google Scholar
• Nian S, Lo ACY, Mi Y, et al. Neurovascular unit in diabetic retinopathy: pathophysiological roles and potential therapeutical targets. Eye and Vision. 2021;8:15.
   Google Scholar
• Mboussou, Y. Histology of Macula in OCT. 2017 [cited 2023 Mar 23]; Available from: https://commons.wikimedia.org/wiki/File:Macula_Histology_OCT.jpg.
   Google Scholar